Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

MAHA advocates are skeptical of President Donald Trump's deal to lower drug prices for GLP-1 anti-obesity drugs.

The agreements with pharma giants Eli Lilly and Novo Nordisk could bring the price of the GLP-1 injectables from roughly ...

Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight ...

Get the latest analysis on Heron Therapeutics (HRTX): current challenges, future outlook, and key growth factors. Click here ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.

President Donald Trump has announced a major deal with Eli Lilly and Novo Nordisk to expand coverage and reduce prices for ...

The list prices of obesity drugs Wegovy and Zepbound are over $1,000, but that’s not necessarily what you pay.

Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...

ASTRAZENECA delivered better-than-expected third quarter earnings and retained its full-year forecasts on Thursday, with strong sales of its blockbuster cancer and cardiovascular drugs.

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...